No Data
No Data
Beijing Succeeder Technology Inc. (688338.SH): intends to repurchase 50-100 million yuan of company's shares.
On June 27th, Gelunhui reported that Beijing Succeeder Technology Inc. (688338.SH) plans to repurchase company stocks with a total amount of no less than 50 million yuan and no more than 100 million yuan. The repurchase price will not exceed 34.5 yuan per share and will be used to implement employee shareholding plans or stock-based incentive plans.
Beijing Succeeder Technology Inc. (688338.SH): The chairman proposed that the company repurchase shares.
On June 21st, Gelun Hui reported that Beijing Succeeder Technology Inc. (stock code 688338.SH) received a letter from the company's chairman, Mr. Wu Shiming, proposing that the company repurchase its own shares using the excess funds and its own capital through the method of centralized bidding transaction. The total amount of funds used to repurchase shares should be no less than RMB 50 million and no more than RMB 100 million.
Secoside (688338.SH) 2023 annual equity distribution: $0.26 per share, share registration on June 5
Secoside (688338.SH) issued the 2023 equity distribution implementation notice. This time, profits will be distributed to Israel...
Secoside (688338.SH): The company's instrument installation recovery is growing significantly in 2023
Gelonghui, May 23丨Secoside (688338.SH) recently said during a survey receiving institutional investors that during the epidemic, the diagnosis and treatment activities of terminal hospitals in some regions of the country were drastically reduced, which led to a decline in the hospital's demand for testing related to the use of the company's products, which in turn had a certain impact on the main business. In 2023, the company's instrument installation recovery trend was obvious. At the same time, the SF-9200 fully automatic coagulation analyzer product was put on the market. Currently, the product has excellent performance in terms of testing speed, degree of automation, accuracy, etc., and has been put into use in many tertiary hospitals after completing installation and evaluation, and has obtained
Secoside (688338.SH) reported 2023 results, net profit of 117 million yuan, an increase of 12.29% year-on-year
Secoside (688338.SH) released its 2023 annual report, achieving revenue of 275 million yuan, with...
Secoside (688338.SH): Overseas markets are important markets with potential for future development of domestic coagulation testing equipment
GLONGHUI, March 11丨Secoside (688338.SH) recently said during an investigation by institutional investors that the company's products, such as blood coagulation testers, reagents, and blood sedimentation testers, have been exported to Turkey, Iran, India, Vietnam, Peru and other countries. The company attaches great importance to the development of overseas business. The overseas market is an important market with potential for future development of domestic coagulation testing equipment. In the future, the company will strive to increase overseas business revenue. In 2023, the company's fully automatic coagulation analyzer passed the European Union IVDRCE registration, laying the foundation for future expansion of the international market.
No Data